Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
Total Valuation
SAGE Therapeutics has a market cap or net worth of $421.76M. The enterprise value is -$159.92M.
Market Cap$421.76M
Enterprise Value-$159.92M
Share Statistics
SAGE Therapeutics has 61.48M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61.48M
Owened by Insiders0.72%
Owened by Instutions26.23%
Financial Efficiency
SAGE Therapeutics’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -90.66%.
Return on Equity (ROE)-86.15%
Return on Assets (ROA)-73.22%
Return on Invested Capital (ROIC)-90.66%
Return on Capital Employed (ROCE)-90.91%
Revenue Per Employee$116,835.694
Profits Per Employee-$1,135,031.161
Employee Count353
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of SAGE Therapeutics is -0.82. SAGE Therapeutics’s PEG ratio is 0.03.
PE Ratio-0.82
PS Ratio8.00
PB Ratio0.71
Price to Fair Value0.71
Price to FCF-1.23
Price to Operating Cash Flow-1.23
PEG Ratio0.03
Income Statement
In the last 12 months, SAGE Therapeutics had revenue of $41.24M and earned -$400.67M in profits. Earnings per share was -$6.60.
Revenue$41.24M
Gross Profit$31.80M
Operating Income-$431.77M
Pretax Income-$400.67M
Net Income-$400.67M
EBITDA-409.74M
Earnings Per Share (EPS)-6.60
Cash Flow
In the last 12 months, operating cash flow was -$267.19M and capital expenditures $0.00, giving a free cash flow of -$267.19M billion.
Operating Cash Flow-$267.19M
Free Cash Flow-$267.19M
Free Cash Flow per Share-$4.35
Dividends & Yields
SAGE Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-80.98%
Earnings Yield-121.43%
Stock Price Statistics
Beta1.78
52-Week Price Change-59.69%
50-Day Moving Average7.52
200-Day Moving Average7.65
Relative Strength Index (RSI)50.55
Average Volume (3m)1.33M
Important Dates
SAGE Therapeutics upcoming earnings date is May 6, 2025, Before Open.
Last Earnings DateFeb 11, 2025
Next Earnings DateMay 6, 2025
Ex-Dividend Date―
Financial Position
SAGE Therapeutics as a current ratio of 7.42, with Debt / Equity ratio of 0.03
Current Ratio7.42
Quick Ratio7.42
Debt to Market Cap0.04
Net Debt to EBITDA0.17
Interest Coverage Ratio0.00
Taxes
In the past 12 months, SAGE Therapeutics has paid $292.72K in taxes.
Income Tax$292.72K
Effective Tax Rate0.00%
Enterprise Valuation
SAGE Therapeutics EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -0.98.
EV to Sales6.32
EV to EBITDA-0.64
EV to Free Cash Flow-0.98
EV to Operating Cash Flow-0.98
Balance Sheet
SAGE Therapeutics has $504.42M in cash and marketable securities with $11.84M in debt, giving a net cash position of -$492.58M billion.
Cash & Marketable Securities$504.42M
Total Debt$11.84M
Net Cash-$492.58M
Net Cash Per Share-$8.01
Tangible Book Value Per Share$7.65
Margins
Gross margin is 77.10%, with operating margin of -1048.35%, and net profit margin of -971.48%.
Gross Margin77.10%
Operating Margin-1048.35%
Pretax Margin-971.48%
Net Profit Margin-971.48%
EBITDA Margin-992.86%
EBIT Margin-995.36%
Analyst Forecast
The average price target for SAGE Therapeutics is $8.27, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$8.27
Price Target Upside24.17%
Analyst ConsensusHold
Analyst Count17
Revenue Growth Forecast-52.30%
EPS Growth Forecast27.13%